Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2021 Earnings Presentation
14 slides from Alkem Laboratories's earnings presentation, Aug 7, 2020
Slide 1: Cover letter to stock exchanges
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem .com • Website: www.alkemlabs.com • CIN· L00305MH1973PLC174201 07 th August, 2020 The Cor
Slide 2: Alkem reports Q1FY21 Results
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem reports
Slide 3: Operational Highlights: Therapy Segments and International Business
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 With a significant part of
Slide 4: Q1FY21 Conference Call details
ALKEM LABORATORIES LTD. <8> ALKEM Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q1FY21 Conference Call at 4
Slide 5: Alkem Laboratories Ltd. Q1FY21
<a> ALKEM Alkem Laboratories Ltd. Investor Presentation Q1FY21 – August 7, 2020 •••• 4> A1KE ■ ~ ~~~~ JI ~ •••,. ~~ ~~~111■■
Slide 6: Safe Harbor Statement
<a> ALKEM Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assump
Slide 7: Key Highlights of Q1FY21
<a> Key Highlights of Q1FY21 ALKEM Resilient performance amidst unprecedented times • Revenue from Operations grew by 8.3% YoY during the quarter, accompanied by significant expansion in EBITDA margin to 26.6% compared to 14.3% in Q1FY20 • Profit After Tax grew by 127.5% compared to the previous yea
Slide 8: Key Financial Highlights – Q1FY21 (Consolidated)
<a> Key Financial Highlights – Q1FY21 (Consolidated) ALKEM All figures in ₹ mn Revenue from Operations India sales ! I YoY: (5.5)% ! 12,222 11,550 I l 20,035 ! I 18,495 ! I lI ! Q1FY20 Q1FY21 I I ! International sales l I 7,853 I ! \ 5,912 I ! I Q1FY20 Q1FY21 ! I l ! : Q1FY20 Q1FY21
Slide 9: Key Financial Highlights – Q1FY21 (Consolidated)
<a> Key Financial Highlights – Q1FY21 (Consolidated) ALKEM All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 12,696 5,332 11,377 r-_ _ _ _...:- 2,645 61.5% 63.4% 14.3% 26.6% !' '-------------'] Q1FY20 Q1FY21 I Q1FY20 Q1FY21 - - - - - - - - -----------------------------------
Slide 10: India Business
<8> India Business ALKEM India Business: Q1FY21 Sales of ₹ 11,550 million (5.5% YoY decline) • India sales contributed 59.5% to total sales in Q1FY21 • Shutdown in clinics, hospital OPDs and deferment of surgeries due to COVID-19 lockdown significantly impacted the new prescription generation during
Slide 11: US Business
<8> US Business ALKEM US Business: Q1FY21 Sales of ₹ 6,664 million (38.3% growth YoY) • US sales contributed 34.3% to total sales in Q1FY21 • Growth in US dollar terms was 28.4% YoY • In Q1FY21, the Company filed 4 ANDAs with the US FDA and received 2 approvals (including 1 tentative approval) • As
Slide 12: Other International Business
<a> Other International Business ALKEM Other International Business: Q1FY21 Sales of ₹ 1,189 million (8.6% YoY growth) • Other International Market sales contributed 6.1% to total sales in Q1FY21 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Chile
Slide 13: Latest Shareholding Pattern
<a> Latest Shareholding Pattern ALKEM Shareholding pattern as on June 30, 2020 Non-Institution, 21.80% Promoter & Promoter Group, Institution, 62.43% 15.76% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, O
Slide 14: Thank You
<a> ALKEM Thank You For further information or queries please contact Gagan Borana Investor Relations – Alkem Laboratories Ltd. Tel: +91 22 3982 9960 E-mail: gagan.borana@alkem.com